Jenburkt Pharmaceuticals Intrinsic Value
Jenburkt Pharmaceuticals (JENBURPH) median intrinsic value is ₹860.00 from 9 valuation models (range ₹752–₹1732), vs current price ₹1157.65 — -25.7% downside (Trading Above Calculated Value), margin of safety -34.6%. Also explore JENBURPH price movement history to track price trends across different timeframes.
JENBURPH Valuation Methods Summary — DCF, Graham Number & P/E
Jenburkt Pharmaceuticals intrinsic value across 9 models vs current price ₹1157.65 — upside/downside and value range per method. For current market price and key ratios, visit Jenburkt Pharmaceuticals share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹1731.62 | ₹1385.30 - ₹2077.94 | +49.6% | EPS: ₹78.71, Sector P/E: 22x |
| Book Value Method | asset | ₹860.00 | ₹774.00 - ₹946.00 | -25.7% | Book Value/Share: ₹430.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹845.00 | ₹760.50 - ₹929.50 | -27.0% | Revenue/Share: ₹422.50, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1000.00 | ₹900.00 - ₹1100.00 | -13.6% | EBITDA: ₹40.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹752.02 | ₹601.62 - ₹902.42 | -35.0% | CF Growth: 8.8%, Discount: 15% |
| PEG Ratio Method | growth | ₹807.36 | ₹726.62 - ₹888.10 | -30.3% | EPS Growth: 12.8%, Fair P/E: 10.3x |
| Growth Adjusted P/E | growth | ₹1221.89 | ₹1099.70 - ₹1344.08 | +5.5% | Revenue Growth: 7.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1190.00 | ₹1071.00 - ₹1309.00 | +2.8% | ROE: 19.8%, P/E Multiple: 14x |
| Graham Defensive Method | conservative | ₹860.00 | ₹774.00 - ₹946.00 | -25.7% | EPS: ₹78.71, BVPS: ₹430.00 |
JENBURPH Intrinsic Value vs Market Price — All Valuation Models
Jenburkt Pharmaceuticals fair value range ₹752–₹1732 vs current market price ₹1157.65 across 9 valuation models. Browse JENBURPH balance sheet details for revenue, profit, balance sheet and cash flow data.
JENBURPH Intrinsic Value Analysis — Undervalued or Overvalued?
Jenburkt Pharmaceuticals median intrinsic value ₹860.00, current price ₹1157.65 — Trading Above Calculated Value by 25.7%, margin of safety -34.6%.
What is the intrinsic value of JENBURPH?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Jenburkt Pharmaceuticals (JENBURPH) is ₹860.00 (median value). With the current market price of ₹1157.65, this represents a -25.7% variance from our estimated fair value.
The valuation range spans from ₹752.02 to ₹1731.62, indicating ₹752.02 - ₹1731.62.
Is JENBURPH undervalued or overvalued?
Based on our multi-method analysis, Jenburkt Pharmaceuticals (JENBURPH) appears to be trading above calculated value by approximately 25.7%.
JENBURPH Financial Health — Key Ratios vs Industry Benchmarks
Jenburkt Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.50 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 19.8% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 24.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.86x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
JENBURPH Cash Flow Quality — Operating & Free Cash Flow
Jenburkt Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹28 Cr | ₹20 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹8 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹17 Cr | ₹17 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹9 Cr | ₹9 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹20 Cr | ₹11 Cr | Positive Free Cash Flow | 8/10 |